Drug Trial Radar · NCT00762190
Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
348
Actual
Start
Nov 2003
Primary completion
Dec 2004
Study completion Dec 2004
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.
Conditions
- Diabetes Mellitus
Interventions
TAK-559 and insulinDrug
TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
InsulinDrug
TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse events.Time frame: All visits or at occurrence.
- Clinical safety lab tests.Time frame: Weeks 12, 24, and Final Visit.
- 12-lead electrocardiogram.Time frame: Weeks: 24 and Final Visit.
- Urinalysis.Time frame: Weeks: 12, 24, 36, 48 and Final Visit.
- Change from Baseline in Blood pressure and pulse.Time frame: At all visits.
- Change from Baseline in Body weight.Time frame: At all visits.
- Left ventricular mass index by body surface area measured by echocardiogram.Time frame: Weeks: 24 and Final Visit.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.